18th Jun 2020 16:46
Hutchison China MediTech Ltd - Hong Kong -based biopharmaceutical company - Gets Fast Track Designation from US Food & Drug Administration for the development of fruquintinib, for the treatment of patients with metastatic colorectal cancer. Initiating a Phase III registration study, known as the Fresco-2 study, in refractory metastatic colorectal cancer in the US, Europe and Japan. Study is expected to start enrolling patients in mid-2020.
Current stock price: 370.00 pence
Year-to-date change: down 7.5%
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed